MAPT and early-onset autosomal dominant Alzheimer disease: We propose AQP4 as an interesting therapeutic target for Alzheimer’s disease, due to its plausible effects in Aβ and tau clearance and ameliorating of neuronal function, making it a target of enormous relevance to the field of ageing and neurodegeneration.